• 1-631-338-8059        

CD Solid Tumor CNV Reference Mix, 3 copies, 12 genes

CAT Size Inquiry Basket
CNVR009 1 x 20 µl
OverviewFeaturesSpecifications
Overview

Product Description

Our CD CNV Reference Mix is designed to address the genomic changes known as Copy Number Variations (CNV), including amplifications and losses, in comparison to a reference genome. Our CNV Reference Mix provides a single sample with three clinically-relevant CNVs, minimizing acquisition and sequencing costs while enabling laboratories to develop, optimize, and validate their assays for detecting a range of copy numbers, including amplifications.
CD CNV Reference Mix offers an extensive selection of essential genes associated with solid tumors, including 12 genes, AKT2, BRAF, EGFR, ERBB2, FGFR3, KIT, KRAS, MET, MYC, MYCN, NTRK1, PIK3CA, each represented with varying copies reflecting the diverse CNV landscape in these cancers.

Features

Key Features & Advantages

Amount: 200 ng/each
Genes: AKT2, BRAF, EGFR, ERBB2, FGFR3, KIT, KRAS, MET, MYC, MYCN, NTRK1, PIK3CA
Copy Numbers: 3
Buffer: 1 mM Tris / 0.1 mM EDTA / 10 mM Potassium Chloride pH 8.0
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Specifications

Product Specifications

Method: Validated Method: digital PCR
Concentration: 10 ng/μL
Application: Our CNV Reference Mix provides a single sample with three clinically-relevant CNVs, minimizing acquisition and sequencing costs while enabling laboratories to develop, optimize, and validate their assays for detecting a range of copy numbers, including amplifications.
Storage: Store at -20°C
* For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
  • SUITE 111, 17 Ramsey Road, Shirley, NY 11967, USA
  • 1-631-338-8059
  • 1-631-614-7828
Copyright © 2025 CD Genomics. All rights reserved.
Top
0
Inquiry Basket
There is no product in the inquiry basket.

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x